What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Richard Conway RichardPAConway
3 years 6 months ago
Cantoni et al. Maladaptive trained immunity in GCA. Aberrant activation of trained immunity programs in myelomonocytic cells leads to sustained and enhanced inflammatory activation and increased expression inflammatory cytokines (esp IL6) @RheumNow #EULAR2022 POS0492 https://t.co/A8t9gV1O3d
Richard Conway RichardPAConway
3 years 6 months ago
Charles-Schoeman et al. ORAL Surveillance, post-hoc analysis of risk factor combinations. 65+ ever smokers appear at particular risk @RheumNow #EULAR2022 POS0674 https://t.co/UyTOITBTX9
David Liew drdavidliew
3 years 6 months ago
If rheumatoid arthritis comes and goes before a rheumatologist lays their hands on it, is it really RA?
We're born skeptical on this. Ronald van Vollenhoven poses questions on what it means for studying drug-free remission in established RA disease #EULAR2022 @RheumNow https://t.co/9GJoqYtVBP
Richard Conway RichardPAConway
3 years 6 months ago
Dr Aggarwal @docrota et al. Abatacept RCT in IIM. Overall negative trial. Pre-specified and post-hoc analyses suggest some benefit in PM/ANM but not in DM @RheumNow #EULAR2022 POS0839 https://t.co/uttMLKy9fW
Richard Conway RichardPAConway
3 years 6 months ago
Palmowski et al. Glucocorticoids and bone density in GCA/PMR/other vasculitis from Rh-GIOP. Weird one, no increase in osteoporosis, no association with current or cumulative steroid dose and osteoporosis. Low BMI, vert #, PPIs were assoc osteoporosis. @RheumNow #EULAR2022 POS1139 https://t.co/n3d6YArXmU
Dr. Antoni Chan synovialjoints
3 years 6 months ago
The two forms of Axial PsA - classical (Axial SpA like) and alternative. Plenary session today #EULAR2022 by Prof. Philip Helliwell. I will be discussing this further in my vlog @RheumNow https://t.co/hxAhgMhHlJ
Dr. Antoni Chan synovialjoints
3 years 6 months ago
Quote of the day “Don’t be too quick to call it negative” by Marco Gattorno on looking for systemic Autoinflammatory disease (SAID) when there is the clinical suspicion #EULAR2022 @RheumNow https://t.co/SjARIlDjtR
David Liew drdavidliew
3 years 6 months ago
Agree. Love to understand:
- standardisation for whole body MRI
- how it does not compromise image quality vs limited field
- clear explanation of benefit vs limited field, where it exists
Its inappropriate use in the worried well by charlatans has skewed me #EULAR2022 @RheumNow https://t.co/3LRz0OOAEF
Richard Conway RichardPAConway
3 years 6 months ago
Castrejon et al. BIOBADASER registry study. Cancer risk with various bDMARDs. Overall I don't think there is a difference here. Lowest in IL17i and highest in abatacept but older and comorbidity confounders @RheumNow #EULAR2022 #POS1439 https://t.co/gfv78ouOTJ
Richard Conway RichardPAConway
3 years 6 months ago
Kristensen et al. IL23i Risankizumab improves fatigue, health related quality of life, work productivity in PsA. @RheumNow #EULAR2022 POS1042 https://t.co/fnoCZCpwNM
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
Please see my short video on Promising Safety Outlook for Rituximab and Baricitinib in Vaccinated Patients #EULAR2022 @RheumNow https://t.co/bqzdWIzoOg
Richard Conway RichardPAConway
3 years 6 months ago
De Miguel et al. Subclinical GCA in PMR shows different US pattern to classic GCA. Less cranial involvement and more isolated extra-cranial. About what you would have expected given clinical manifestations. @RheumNow #EULAR2022 POS0248 https://t.co/i9IZBdF1vQ
Richard Conway RichardPAConway
3 years 6 months ago
Joanna Robson @Robsonjo4 et al. Disease specific outcome measure for GCA (badly needed!) GCA-PROM. Demonstrated internal and external validity in measuring health related quality of life in GCA patients. @RheumNow #EULAR2022 POS0003 https://t.co/F8pLvlzqD1
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
Please see my video interview with Dr @LucyCarter6 on her prize winning #EULAR2022 abstract #OP0234 on transcriptomic analyses of peripheral bloods in identifying modules that predict OR protect progression from ANA+ to #lupus or CTD @RheumNow https://t.co/c3khwFzx79
Richard Conway RichardPAConway
3 years 6 months ago
Nash @drpnash et al. IL23i guselkumab improves pain in PsA. Good to see as it is a really important PRO, but there is still significant work to do, week 24 - 60% had <50% and 37% had <20% improvement in pain @RheumNow #EULAR2022 POS1044 https://t.co/H92r4leslT
Poster Hall